NewsMeter
Food and Drug Administration clearance for its Investigational New Drug application for SZN-8141 on October 2, 2026.
This regulatory approval allows the company to move the program into clinical trials after the mandatory 30-day review window closed.
The drug candidate is a bifunctional antibody that acts as both a Wnt agonist and a vascular endothelial growth factor antagonist. Surrozen is developing it as an intravitreal injection to treat diabetic macular edema.
The company anticipates dosing the first patient in the DUET Phase 1b/2a study during the fourth quarter of 2026. Preliminary results from this trial are projected for the second half of 2027.
Keep reading